{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:51:46Z","timestamp":1692852706504},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1007\/bf02710170","type":"journal-article","created":{"date-parts":[[2007,9,22]],"date-time":"2007-09-22T13:18:57Z","timestamp":1190467137000},"page":"244-249","source":"Crossref","is-referenced-by-count":4,"title":["Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy"],"prefix":"10.1007","volume":"7","author":[{"given":"Carlos","family":"Garc\u00eda-Gir\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s Garc\u00eda","family":"Palomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Alonso","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel Le\u00f3n","family":"Carbonero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel M\u00e9ndez","family":"Urena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Encarna Adr\u00f3ver","family":"Cebri\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n Barcel\u00f3","family":"Gal\u00edndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica Arroyo","family":"Yustos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 \u00c1lvarez","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02710170_CR1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/bega.2001.0280","volume":"16","author":"J Faivre","year":"2002","unstructured":"Faivre J, Bouvier AM, Bonithon-Kopp C. Epidemiology and screening of colorectal cancer. Best Pract Res Clin Gastroenterol. 2002;16:187\u201399.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"BF02710170_CR2","first-page":"11","volume":"15","author":"DG Haller","year":"2001","unstructured":"Haller DG. Update on chemotherapy for advanced colorectal cancer. Oncology (Huntingt). 2001;15:11\u20135.","journal-title":"Oncology (Huntingt)"},{"key":"BF02710170_CR3","first-page":"589","volume":"26","author":"HJ Schmoll","year":"1999","unstructured":"Schmoll HJ, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol. 1999; 26:589\u2013605.","journal-title":"Semin Oncol"},{"key":"BF02710170_CR4","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2001.19.5.1501","volume":"19","author":"U Vanhoefer","year":"2001","unstructured":"Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001;19:1501\u201318.","journal-title":"J Clin Oncol"},{"key":"BF02710170_CR5","first-page":"641","volume":"8","author":"R Garc\u00eda-Carbonero","year":"2002","unstructured":"Garc\u00eda-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002;8:641\u201361.","journal-title":"Clin Cancer Res"},{"key":"BF02710170_CR6","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1200\/JCO.1993.11.11.2194","volume":"11","author":"ML Rothenberg","year":"1993","unstructured":"Rothenberg ML, Kuhn JG, Burris HA, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993;11:2194\u2013204.","journal-title":"J Clin Oncol"},{"key":"BF02710170_CR7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1995.13.1.210","volume":"13","author":"D Abigerges","year":"1995","unstructured":"Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol. 1995;13:210\u201321.","journal-title":"J Clin Oncol"},{"key":"BF02710170_CR8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/jnci\/83.16.1164","volume":"83","author":"S Negoro","year":"1991","unstructured":"Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 1991;83:1164\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"BF02710170_CR9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1023\/A:1013157727506","volume":"12","author":"ML Rothenberg","year":"2001","unstructured":"Rothenberg ML, Kuhn JG, Schaaf LJ, et al. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol. 2001; 12:1631\u201341.","journal-title":"Ann Oncol"},{"key":"BF02710170_CR10","first-page":"425","volume":"72","author":"RL Capizzi","year":"2000","unstructured":"Capizzi RL, Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol. 2000;72:425\u201335.","journal-title":"Int J Hematol"},{"key":"BF02710170_CR11","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.10432","volume":"94","author":"ML Delioukina","year":"2002","unstructured":"Delioukina ML, Prager D, Parson M, Hecht JR, Rosen P, Rosen LS. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer. 2002;94:2174\u20139.","journal-title":"Cancer"},{"key":"BF02710170_CR12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207\u201314.","journal-title":"Cancer"},{"key":"BF02710170_CR13","first-page":"1","volume-title":"Guidelines for the reporting of adverse drug reactions","author":"National Cancer Institute","year":"1999","unstructured":"National Cancer Institute. Guidelines for the reporting of adverse drug reactions. MD, Division of Cancer Treatment, National Cancer Institute; 1999:1\u201380."},{"key":"BF02710170_CR14","unstructured":"Rothenberg ML, Hainsworth JD, Rosen LS, et al. Phase II study of irinotecan (CPT-11) 250 mg\/m2 given every-ot-her-week in previously treated colorectal cancer patients (abstract 1092). Proc Am Soc Clin Oncol. 1998:284a."},{"key":"BF02710170_CR15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0959-8049(98)00353-0","volume":"35","author":"E Cutsem Van","year":"1999","unstructured":"Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer. 1999;35:54\u20139.","journal-title":"Eur J Cancer"},{"key":"BF02710170_CR16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF02713045","volume":"4","author":"M Navarro","year":"2002","unstructured":"Navarro M, Losa F, Manzano H, et al. Irinotecan (CPT-11) as first-line monotherapy in patients with advanced, metastatic colorectal cancer refractory to 5-fluorouracil adjuvant chemotherapy: a multicenter phase II study. Rev Oncol. 2002;4:385\u201390.","journal-title":"Rev Oncol"},{"key":"BF02710170_CR17","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1358\/mf.2003.25.8.778085","volume":"25","author":"A Anton","year":"2003","unstructured":"Anton A, Aranda E, Carrato A, et al. Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. Methods Find Exp Clin Pharmacol. 2003;25:639\u201343.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"BF02710170_CR18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905\u201314.","journal-title":"N Engl J Med"},{"key":"BF02710170_CR19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","volume":"15","author":"P Rougier","year":"1997","unstructured":"Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997;15:251\u201360.","journal-title":"J Clin Oncol"},{"key":"BF02710170_CR20","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","volume":"352","author":"D Cunningham","year":"1998","unstructured":"Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413\u20138.","journal-title":"Lancet"},{"key":"BF02710170_CR21","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","volume":"352","author":"P Rougier","year":"1998","unstructured":"Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407\u201312.","journal-title":"Lancet"},{"key":"BF02710170_CR22","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9","volume":"85","author":"ML Rothenberg","year":"1999","unstructured":"Rothenberg ML, Cox JV, DeVore RF, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999;85:786\u201395.","journal-title":"Cancer"},{"key":"BF02710170_CR23","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1200\/JCO.1997.15.8.2910","volume":"15","author":"HC Pitot","year":"1997","unstructured":"Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 1997;15:2910\u20139.","journal-title":"J Clin Oncol"},{"key":"BF02710170_CR24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00280-003-0659-z","volume":"52","author":"N Tsavaris","year":"2003","unstructured":"Tsavaris N, Ziras N, Kosmas C, et al. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. Cancer Chemother Pharmacol. 2003;52:514\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02710170_CR25","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.2002.08.015","volume":"20","author":"J Souglakos","year":"2002","unstructured":"Souglakos J, Mavroudis D, Kakolyris S, et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol. 2002;20:2651\u20137.","journal-title":"J Clin Oncol"},{"key":"BF02710170_CR26","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/annonc\/mdf133","volume":"13","author":"P Comella","year":"2002","unstructured":"Comella P, Crucitta E, De Vita L, et al. Addition of either irinotecan or methotrexate to bolus 5-fluoruracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Annals Oncol. 2002; 13:866\u201373.","journal-title":"Annals Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02710170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02710170\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02710170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T06:33:05Z","timestamp":1684045985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02710170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["BF02710170"],"URL":"https:\/\/doi.org\/10.1007\/bf02710170","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}